However, CCR4 is also expressed on the surface of type 2 helper T (Th2) cells and skin homing T cells, so the CCR4 antibody Mogamulizumab is currently only approved for cutaneous T cell lymphomas, whose malignant T-cells are skin-homing T-cells and which exhibit a high CCR4-expressing Th2 and Treg phenotypes (21). The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.